In SURMOUNT-1, published in NEJM in 2022, tirzepatide at the 15 mg weekly dose produced a mean placebo-adjusted body weight reduction of 17.8% at 72 weeks in adults with obesity (Jastreboff et al., NEJM, 2022)
Key Improvements Over GHK-CU When to Choose SRCP Over GHK-CU SRCP formulations excel in specific situations where first-generation copper peptides fall short
Wu P, Peters JM, Harris RA
.220 mg *
Kovalzon and Strekalova, summarizing the field in 2006, were explicit: the link between DSIP and sleep had never been further characterized, in part because of the lack of isolation of the DSIP gene, protein and possible related receptor, and the hypothesis of DSIP as a sleep factor was extremely poorly documented and still weak (Kovalzon & Strekalova, 2006)
r 2 = 0.99, R = 1) with spiked GSH concentration showing consistent recovery of the extraction procedure